Avid Bioservices Inc (CDMO)

[eb0783]

Sun. What would you expect with a tiny partnership, anything, 25Mil for a fraction of an indication, lets say Breast Cancer, on PPHM share price?

Doubt that there will be any “tiny” partnerships. Part of the problem has always been that there is no way to only sell bavi for one or a couple of indications because once approved, it can be used off-label for just about anything the doctors want to use it for. AND, it will eventually be used against viruses (among many other uses) but doubt that use will demand the high prices that oncology does. So think about that issue where the viral regimen might “only” sell for $20,000 but the oncology regimen might be worth $80,000. (just picking numbers here but the difference between will undoubtedly be large)

I think they already know that the best they can do, partnership wise, is by splitting via geographic areas. That will be significant no matter how it is split up.